Deridre Kelly, Medical Oncologist at Mater Misericordiae University Hospital, shared a post on X:
“Immuno Oncology: Anti–PD-L1 and TKI in anaplastic thyroid cancer.
Median OS: 19 mosBRAF V600E-mutated patients: 43 mos (50% ORR)
Longest OS in ATC history!
Targeted and immunotherapy synergy outcomes.”
